92 related articles for article (PubMed ID: 26881532)
1. Preliminary dosimetry of (166)Ho-propylene di-amino tetra (methy1enephosphonicacid) for human based on biodistribution data in rats.
Zolghadri S; Yousefnia H; Jalilian AR; Shiri-Yekta Z; Maragheh MG
J Cancer Res Ther; 2015; 11(4):862-7. PubMed ID: 26881532
[TBL] [Abstract][Full Text] [Related]
2. Estimation of human absorbed dose for (166)Ho-PAM: comparison with (166)Ho-DOTMP and (166)Ho-TTHMP.
Vaez-Tehrani M; Zolghadri S; Yousefnia H; Afarideh H
Br J Radiol; 2016 Oct; 89(1066):20160153. PubMed ID: 27524266
[TBL] [Abstract][Full Text] [Related]
3. Development of (166)Holmium-1,2 Propylene Di-amino Tetra (Methy1enephosphonicacid) as a Possible Bone Palliation Agent.
Zolghadri S; Jalilian AR; Yousefnia H; Bahrami-Samani A; Ghannadi-Maragheh M
World J Nucl Med; 2014 Jan; 13(1):28-33. PubMed ID: 25191109
[TBL] [Abstract][Full Text] [Related]
4. Production, quality control, biodistribution assessment and preliminary dose evaluation of (177)Lu-PDTMP as a possible bone palliative agent.
Yousefnia H; Jalilian AR; Zolghadri S; Ghannadi-Maragheh M
Nucl Med Commun; 2014 Jan; 35(1):99-107. PubMed ID: 24162837
[TBL] [Abstract][Full Text] [Related]
5. Production, Quality Control and Biological Evaluation of (166)Ho-PDTMP as a Possible Bone Palliation Agent.
Zolghadri S; Jalilian AR; Naseri Z; Yousefnia H; Bahrami-Samani A; Ghannadi-Maragheh M; Afarideh H
Iran J Basic Med Sci; 2013 May; 16(5):719-25. PubMed ID: 23826495
[TBL] [Abstract][Full Text] [Related]
6. Preliminary dosimetric evaluation of (166)Ho-TTHMP for human based on biodistribution data in rats.
Yousefnia H; Zolghadri S; Jalilian AR; Tajik M; Ghannadi-Maragheh M
Appl Radiat Isot; 2014 Dec; 94():260-265. PubMed ID: 25255303
[TBL] [Abstract][Full Text] [Related]
7. Preparation of (166)Dy/(166)Ho-EDTMP: a potential in vivo generator system for bone marrow ablation.
Pedraza-López M; Ferro-Flores G; de Murphy CA; Tendilla JI; Villanueva-Sánchez O
Nucl Med Commun; 2004 Jun; 25(6):615-21. PubMed ID: 15167523
[TBL] [Abstract][Full Text] [Related]
8. Dosimetry and toxicity of Quadramet for bone marrow ablation in multiple myeloma and other haematological malignancies.
Bartlett ML; Webb M; Durrant S; Morton AJ; Allison R; Macfarlane DJ
Eur J Nucl Med Mol Imaging; 2002 Nov; 29(11):1470-7. PubMed ID: 12397466
[TBL] [Abstract][Full Text] [Related]
9. Ethylene diamine tetramethylene phosphonic acid labeled with various β(-)-emitting radiometals: labeling optimization and animal biodistribution.
Sohaib M; Ahmad M; Jehangir M; Perveen A
Cancer Biother Radiopharm; 2011 Apr; 26(2):159-64. PubMed ID: 21510750
[TBL] [Abstract][Full Text] [Related]
10. 166Ho-DOTMP radiation-absorbed dose estimation for skeletal targeted radiotherapy.
Breitz HB; Wendt RE; Stabin MS; Shen S; Erwin WD; Rajendran JG; Eary JF; Durack L; Delpassand E; Martin W; Meredith RF
J Nucl Med; 2006 Mar; 47(3):534-42. PubMed ID: 16513624
[TBL] [Abstract][Full Text] [Related]
11. Studies on the preparation and stability of samarium-153 propylene diamine tetramethylene phosphonate (PDTMP) complex as a bone seeker.
Majali MA; Mathakar AR; Shimpi HH; Banerjee S; Samuel G
Appl Radiat Isot; 2000 Dec; 53(6):987-91. PubMed ID: 11077962
[TBL] [Abstract][Full Text] [Related]
12. Dosimetry of high dose skeletal targeted radiotherapy (STR) with 166Ho-DOTMP.
Breitz H; Wendt R; Stabin M; Bouchet L; Wessels B
Cancer Biother Radiopharm; 2003 Apr; 18(2):225-30. PubMed ID: 12804048
[TBL] [Abstract][Full Text] [Related]
13. Cytotoxic and genotoxic effect of the [166Dy]Dy/166Ho-EDTMP in vivo generator system in mice.
Pedraza-López M; Ferro-Flores G; Arteaga de Murphy C; Morales-Ramírez P; Piedras-Ross J; Murphy-Stack E; Hernández-Oviedo O
Nucl Med Biol; 2004 Nov; 31(8):1079-85. PubMed ID: 15607490
[TBL] [Abstract][Full Text] [Related]
14. Characterization of the [(153)Sm]Sm-EDTMP pharmacokinetics and estimation of radiation absorbed dose on an individual basis.
Vigna L; Matheoud R; Ridone S; Arginelli D; Della Monica P; Rudoni M; Inglese E; Brambilla M
Phys Med; 2011 Jul; 27(3):144-52. PubMed ID: 20864370
[TBL] [Abstract][Full Text] [Related]
15. Estimated human absorbed dose of a new (153)Sm bone seeking agent based on biodistribution data in mice: Comparison with (153)Sm-EDTMP.
Yousefnia H; Zolghadri S
Phys Med; 2015 Nov; 31(7):714-9. PubMed ID: 26095757
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics, dosimetry and toxicity of holmium-166-DOTMP for bone marrow ablation in multiple myeloma.
Bayouth JE; Macey DJ; Kasi LP; Garlich JR; McMillan K; Dimopoulos MA; Champlin RE
J Nucl Med; 1995 May; 36(5):730-7. PubMed ID: 7738641
[TBL] [Abstract][Full Text] [Related]
17. Bone marrow transplantation in dogs after radio-ablation with a new Ho-166 amino phosphonic acid bone-seeking agent (DOTMP).
Parks NJ; Kawakami TG; Avila MJ; White R; Cain GR; Raaka SD; Hornoff W; Fisher P; Moore P; Seibert JA
Blood; 1993 Jul; 82(1):318-25. PubMed ID: 8324232
[TBL] [Abstract][Full Text] [Related]
18. High-dose 166Ho-DOTMP in myeloablative treatment of multiple myeloma: pharmacokinetics, biodistribution, and absorbed dose estimation.
Rajendran JG; Eary JF; Bensinger W; Durack LD; Vernon C; Fritzberg A
J Nucl Med; 2002 Oct; 43(10):1383-90. PubMed ID: 12368378
[TBL] [Abstract][Full Text] [Related]
19. Estimated human absorbed dose of ¹⁷⁷Lu-BPAMD based on mice data: Comparison with ¹⁷⁷Lu-EDTMP.
Yousefnia H; Zolghadri S; Shanehsazzadeh S
Appl Radiat Isot; 2015 Oct; 104():128-35. PubMed ID: 26163291
[TBL] [Abstract][Full Text] [Related]
20. Preparation and Dosimetry Evaluation of a Carrier- Free 90Y Labeled DOTMP as a Promising Agent for Bone Marrow Ablation.
Salek N; Vosoghi S; Arani SS; Samani AB; Mehrabi M; Maraghe MG
Curr Radiopharm; 2018; 11(2):116-122. PubMed ID: 29651974
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
